SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF DAPAGLIFLOZIN TREATING PATIENTS OF TYPE 2 DIABETES MELLITUS (T2DM)

被引：0
|
作者：
Hu, C. [1 ]
Zhang, C. [2 ]
Wang, B. [2 ]
Xu, L. [2 ]
机构：
[1] Astrazeneca, Beijing, Peoples R China
[2] Astrazeneca China, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.295
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB30
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [1] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [2] SYSTEMATIC REVIEW OF THE COST EFFECTIVENESS OF DAPAGLIFLOZIN USED TO TREAT PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Tsan, J.
    Duong, T.
    Girgis, N.
    Labib, M.
    Moustakas, A.
    Loh, F. E.
    [J]. VALUE IN HEALTH, 2018, 21 : S75 - S75
  • [3] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [4] Effectiveness of diabetes self-management education (DSME) in type 2 diabetes mellitus (T2DM) patients: Systematic literature review
    Ernawati, Ucik
    Wihastuti, Titin Andri
    Utami, Yulian Wiji
    [J]. JOURNAL OF PUBLIC HEALTH RESEARCH, 2021, 10 (02)
  • [5] Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) and Concomitant Heart Failure
    Kosiborod, Mikhail
    Gause-Nilsson, Ingrid Ami
    Sonesson, Christian
    Sugg, Jennifer E.
    Johnsson, Eva
    [J]. DIABETES, 2015, 64 : A313 - A313
  • [6] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [7] COST-EFFECTIVENESS ANALYSIS OF XIGDUO (EXTENDED-RELEASE DAPAGLIFLOZIN-METFORMIN TABLETS) FOR MANAGING TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS
    Bao, H.
    Liu, Q.
    Peng, X.
    Xuan, J.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S122 - S122
  • [8] Cardiovascular safety of dapagliflozin in type 2 diabetes mellitus (T2DM) patients with various degrees of cardiovascular risk
    Sonesson, C.
    Frederich, R.
    Johansson, P. A.
    Gause-Nilsson, I.
    Langkilde, A. M.
    List, J. F.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 1072 - 1072
  • [9] EFFICACY AND SAFETY OF TREATMENTS OF TYPE 2 DIABETES MELLITUS (T2DM): A SYSTEMATIC REVIEW (SLR)
    Pettre, S.
    Selya-Hammer, C.
    Ho, S.
    Garg, M.
    Schroeder, M.
    Kaur, V
    Hemels, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A433 - A433
  • [10] RESEARCH ON THE INCIDENCE AND COST OF HYPOGLYCEMIA EPISODE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Zheng, Y.
    Wu, J.
    Oesterle, A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A504 - A505
12345